Breethe
Breethe is a Baltimore-based medical device company developing the Breethe Oxy-1 System, a compact artificial lung that provides extracorporeal oxygenation for cardiac care patients. Acquired by Abiomed (now Johnson & Johnson), it is marketed to hospitals performing heart recovery, protected PCI, and cardiogenic shock procedures.
- Company typePrivate
- Founded2014
- HeadquartersBaltimore, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Breethe does
Breethe is a Baltimore-based medical device company founded in 2014 that develops a compact artificial lung — the Breethe Oxy-1 System — designed to provide extracorporeal oxygenation for patients with acute and chronic lung problems. The system is positioned within cardiac care workflows, specifically supporting heart recovery, protected PCI, and cardiogenic shock management, where it complements Abiomed's Impella heart pump portfolio by oxygenating the body during cardiac procedures. As an 11-50 employee venture-backed company that raised approximately $18.4M across six funding rounds from 2015 to 2019, Breethe was acquired by Abiomed (now a Johnson & Johnson company) and is currently marketed through the HeartRecovery.com platform alongside Abiomed's broader heart recovery product line. The product is listed under "Future Innovations," indicating it remains in an early commercial phase within the larger Abiomed/J&J ecosystem.
The company's go-to-market is channeled through Abiomed's established cardiac care infrastructure, including a 24-hour clinical support hotline (1-800-422-8666) and global regional sites covering North America, Europe (Germany, France), and Asia Pacific (Japan). Customer concentration sits within hospitals performing high-acuity cardiac interventions, where the Breethe Oxy-1 System is deployed as part of integrated heart recovery protocols. The company does not disclose standalone pricing or revenue, and operates as a product line within Johnson & Johnson MedTech rather than as an independently reported entity.
Breethe firmographics
Firmographics- Name
- Breethe
- Website
- https://breethe.life
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Breethe is a Baltimore-based medical device company developing the Breethe Oxy-1 System, a compact artificial lung that provides extracorporeal oxygenation for cardiac care patients. Acquired by Abiomed (now Johnson & Johnson), it is marketed to hospitals performing heart recovery, protected PCI, and cardiogenic shock procedures.
- Ownership category
- akta.pro rank
Breethe industry classification
Industry- Product category
- Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro industry
- Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC)Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management
Keywords
Where Breethe is headquartered
LocationHeadquarters
- HQ city
- Baltimore
- HQ country
- United States
- HQ region
- North America
Markets served
Breethe business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Breethe product offering
Product offeringCore offering
Breethe is a medical device company that develops a compact artificial lung (the Breethe Oxy-1 System) for patients with acute and chronic lung problems. The device provides extracorporeal oxygenation to support cardiac care procedures such as heart recovery, protected PCI, and cardiogenic shock management. The technology integrates into Abiomed's broader cardiac care ecosystem and is intended for use by healthcare professionals in hospital settings.
Differentiator
Problem solved
Functional benefit
Products and services
- Breethe Oxy-1 System A compact artificial lung (extracorporeal oxygenation device) intended for patients with acute and chronic lung problems, providing oxygenation support during heart recovery procedures, protected PCI, and cardiogenic shock management. Sold to hospitals and used by healthcare professionals within the Abiomed/J&J cardiac care portfolio.
Companies that use Breethe
Customer profileSegments1 record
Ideal customer profiles1 record
Breethe technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Breethe partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights5 records
Breethe competitors and assessment
Company assessmentDirect peers
- Terumo (Terumo Cardiovascular / FX05): Terumo Cardiovascular offers oxygenators and ECMO circuits (e.g., FX05 oxygenator, Terumo System 1) used in cardiopulmonary bypass and ECMO. Direct competitor in oxygenation consumables and systems for cardiac surgical and support applications.
- Nipro Corporation: Nipro manufactures hollow-fibre oxygenators and ECMO/ECCO2R systems (e.g., Biocon oxygenator) used in cardiac surgery and respiratory support. Directly comparable as an oxygenation device competitor.
- LivaNova (TandemLife / LifeSPARC): Through its TandemLife/TLS product line, LivaNova offers portable ECMO and oxygenation systems (including LifeSPARC controller) for cardiogenic shock and respiratory failure. Direct competitor in compact oxygenation/ECMO for cardiac care.
- Getinge (Maquet Cardiohelp): Getinge's Maquet Cardiohelp system is a leading portable ECMO/oxygenation platform used in cardiac surgery, cardiogenic shock, and respiratory failure. Directly competes with Breethe Oxy-1 in the compact oxygenation/ECMO category for cardiac and respiratory support.
- Fresenius Medical Care / Xenios (now part of Fresenius): Xenios (acquired by Fresenius) developed i-cor, iLA, and Novalung oxygenation/ECMO devices for cardiac and respiratory support, directly competing with Breethe Oxy-1 in the compact oxygenation category.
Broad incumbents
- Abiomed (Johnson & Johnson MedTech): Acquirer of Breethe and parent of the Oxy-1 system. Abiomed sells the Impella heart pump platform and now offers Breethe as part of its heart-recovery portfolio, making it the most directly aligned commercial vehicle for Breethe's oxygenation technology.
- Medtronic (Affinity Fusion oxygenator): Medtronic manufactures oxygenators and ECMO-related disposables (Affinity Fusion, Nautilus) as part of its broader cardiac surgery portfolio. While not focused exclusively on compact oxygenation, it competes broadly in oxygenation consumables for cardiopulmonary support.
Emerging players
- Inspira Technologies: Inspira is developing compact extracorporeal blood oxygenation and CO2 removal systems (e.g., ART device) for respiratory failure and cardiac support, positioning itself as a next-generation compact oxygenation player similar in concept to Breethe Oxy-1.
- Hemovent: Hemovent develops a portable, self-contained ECMO system (MOBYBOX) with a fully integrated oxygenator and pump, directly targeting the same compact-oxygenation, point-of-care use case as Breethe Oxy-1.
- ALung Technologies: ALung developed the Hemolung Respiratory Assist System (RAS) for extracorporeal CO2 removal (ECCO2R), an adjacent compact respiratory support technology that overlaps with Breethe's oxygenation value proposition.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks4 records
Key highlights6 records
Customer concentration
Breethe financial estimates
Financial estimateRevenue estimate
Valuation estimate
Breethe leadership team
Management profileNumber of profiles
Profiles2 records
Breethe funding detail
Funding detailFunding overview
Funding rounds6 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Breethe M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Breethe
What does Breethe do?
Breethe is a medical device company that develops a compact artificial lung (the Breethe Oxy-1 System) for patients with acute and chronic lung problems. The device provides extracorporeal oxygenation to support cardiac care procedures such as heart recovery, protected PCI, and cardiogenic shock management. The technology integrates into Abiomed's broader cardiac care ecosystem and is intended for use by healthcare professionals in hospital settings.
Is Breethe a public or private company?
Breethe is a private company. It is classified as corporate owned and is currently operating.
When was Breethe founded?
Breethe was founded in 2014. It employs 1 to 10 people.
Where is Breethe based?
Breethe is headquartered in Baltimore, United States, in the North America region.
Who are Breethe's main competitors?
Direct peers on record are Terumo (Terumo Cardiovascular / FX05), Nipro Corporation, LivaNova (TandemLife / LifeSPARC), Getinge (Maquet Cardiohelp) and Fresenius Medical Care / Xenios (now part of Fresenius). Broad incumbents are Abiomed (Johnson & Johnson MedTech) and Medtronic (Affinity Fusion oxygenator). Emerging players are Inspira Technologies, Hemovent and ALung Technologies.
Does Breethe have an API?
No public API is recorded for Breethe.
What industry is Breethe in?
Breethe's product category is Medical Devices. Its primary akta.pro industry code is HLAHAGAD, Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC), with a secondary code of HLAKANAM, Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management. Its NAICS code is 339113 and its SIC code is 3841.